IRIS UniCatt

Coratti, Giorgia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.672
EU - Europa 5.479
AS - Asia 5.199
SA - Sud America 1.004
AF - Africa 147
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 6
Totale 17.518
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.404
SG - Singapore 2.522
DE - Germania 1.259
IT - Italia 1.195
CN - Cina 1.008
BR - Brasile 790
NL - Olanda 775
SE - Svezia 609
VN - Vietnam 547
FR - Francia 458
IE - Irlanda 257
GB - Regno Unito 217
JP - Giappone 184
IN - India 175
CA - Canada 141
HK - Hong Kong 137
FI - Finlandia 135
ID - Indonesia 131
RU - Federazione Russa 105
PL - Polonia 100
AR - Argentina 84
BD - Bangladesh 75
MX - Messico 72
TR - Turchia 71
ES - Italia 68
KR - Corea 67
IQ - Iraq 51
AT - Austria 48
ZA - Sudafrica 44
UA - Ucraina 38
EC - Ecuador 34
CZ - Repubblica Ceca 31
PK - Pakistan 30
BE - Belgio 27
CH - Svizzera 24
IR - Iran 24
VE - Venezuela 24
LT - Lituania 23
PH - Filippine 23
CO - Colombia 20
IL - Israele 18
PA - Panama 18
PY - Paraguay 18
SA - Arabia Saudita 18
AE - Emirati Arabi Uniti 17
RO - Romania 17
EG - Egitto 16
MA - Marocco 16
RS - Serbia 15
UZ - Uzbekistan 15
CI - Costa d'Avorio 14
TN - Tunisia 14
JO - Giordania 13
MK - Macedonia 13
PE - Perù 13
KE - Kenya 11
CL - Cile 10
PT - Portogallo 10
CR - Costa Rica 8
DO - Repubblica Dominicana 8
NP - Nepal 8
BG - Bulgaria 7
DK - Danimarca 7
KZ - Kazakistan 7
MY - Malesia 7
OM - Oman 7
NZ - Nuova Zelanda 6
UY - Uruguay 6
AL - Albania 5
LK - Sri Lanka 5
NG - Nigeria 5
SK - Slovacchia (Repubblica Slovacca) 5
TH - Thailandia 5
AU - Australia 4
BY - Bielorussia 4
DZ - Algeria 4
ET - Etiopia 4
HN - Honduras 4
HU - Ungheria 4
JM - Giamaica 4
KG - Kirghizistan 4
LV - Lettonia 4
SN - Senegal 4
TW - Taiwan 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AZ - Azerbaigian 3
BH - Bahrain 3
BO - Bolivia 3
GE - Georgia 3
GR - Grecia 3
LA - Repubblica Popolare Democratica del Laos 3
LB - Libano 3
LU - Lussemburgo 3
ME - Montenegro 3
SV - El Salvador 3
XK - ???statistics.table.value.countryCode.XK??? 3
AO - Angola 2
BT - Bhutan 2
CG - Congo 2
DM - Dominica 2
Totale 17.477
Salva come PNG Salva come JPEG
Città #
Singapore 1.542
Ashburn 769
Amsterdam 704
San Jose 670
Chandler 597
Frankfurt am Main 309
New York 289
Rome 278
Dublin 228
Los Angeles 206
Beijing 186
Hefei 181
Ho Chi Minh City 180
Tokyo 177
Milan 173
Hanoi 127
Lauterbourg 127
Hong Kong 123
Jakarta 117
Munich 91
São Paulo 88
Dallas 86
Boston 83
Helsinki 74
Warsaw 69
Marseille 68
Seoul 65
Orem 62
Chicago 61
The Dalles 61
Princeton 58
San Mateo 56
Montreal 55
Buffalo 54
Santa Clara 54
Council Bluffs 50
Kent 48
Moscow 48
Atlanta 47
Houston 44
London 44
Denver 43
Nuremberg 42
Poplar 41
Stockholm 41
Paris 38
Brooklyn 35
Chennai 35
Düsseldorf 35
Wilmington 35
Da Nang 33
Palermo 33
Toronto 33
Johannesburg 30
Bremen 28
Haiphong 28
Boardman 27
Lappeenranta 26
Nanjing 26
Mexico City 25
Turku 25
Phoenix 24
Pune 24
Shanghai 23
Ann Arbor 22
Dearborn 22
Ankara 21
Brussels 21
Baghdad 20
Brno 20
Vienna 20
Brasília 19
Columbus 19
Fairfield 19
Belo Horizonte 18
Rio de Janeiro 18
San Francisco 18
Biên Hòa 17
Bologna 17
Dhaka 17
Falkenstein 17
Guangzhou 17
Seattle 17
Turin 17
Charlotte 15
Kish 15
New Delhi 15
Abidjan 14
Bexley 14
Hyderabad 14
Manchester 14
Querétaro 14
Redmond 14
Andover 13
Augusta 13
City of London 13
Washington 13
Wroclaw 13
Amman 12
Buenos Aires 12
Totale 9.673
Salva come PNG Salva come JPEG
Nome #
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 950
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial 643
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 499
Oral and Swallowing Abilities Tool (OrSAT) for Type 1 SMA Patients: Development of a New Module 323
Performance of Upper Limb module for Duchenne muscular dystrophy 234
Assessing floppy infants: a new module 204
Oral and Swallowing Abilities Tool (OrSAT) in nusinersen treated patients 190
Developmental milestones in type I spinal muscular atrophy 187
Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening 187
Predictive models in SMA II natural history trajectories using machine learning: A proof of concept study 176
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 171
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 169
Type I SMA “new natural history”: long-term data in nusinersen-treated patients 165
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 164
Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapies 163
Body mass index in type 2 spinal muscular atrophy: a longitudinal study 161
SMA-miRs (MiR-181a- 5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples 159
SMA-miRs (MiR-181a- 5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples 159
Early neurological signs in infants identified through neonatal screening for SMA: do they predict outcome? 156
Gain and loss of upper limb abilities in Duchenne muscular dystrophy patients: A 24-month study 155
Different trajectories in upper limb and gross motor function in spinal muscular atrophy 153
Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data 151
Hammersmith Infant Neurological Examination in low-risk infants born very preterm: a longitudinal prospective study 151
Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen 149
Revised upper limb module for spinal muscular atrophy: Development of a new module 146
Respiratory function and therapeutic expectations in DMD: Families experience and perspective 146
Can the CHOP-INTEND be used as An Outcome Measure in the First Months of Age? Implications for Clinical Trials and Real World Data 145
Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy 145
Upper limb function in Duchenne muscular dystrophy: 24 month longitudinal data. 144
The nonsense mutation stop+4 model correlates with motor changes in Duchenne muscular dystrophy 144
Type I Spinal Muscular Atrophy patients treated with nusinersen: 4 year follow-up of motor, respiratory and bulbar function 142
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 142
Early Childhood Attention Battery: Italian adaptation and new expanded normative data. 138
Longitudinal motor functional outcomes and magnetic resonance imaging patterns of muscle involvement in upper limbs in duchenne muscular dystrophy 137
6MWT can identify type 3 SMA patients with neuromuscular junction dysfunction 136
Early Gross Motor Milestones in Duchenne Muscular Dystrophy 136
A Longitudinal Follow-Up Study of Intellectual Function in Duchenne Muscular Dystrophy over Age: Is It Really Stable? 135
Type I spinal muscular atrophy and disease modifying treatments: a nationwide study in children born since 2016 135
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 134
Bulbar function in spinal muscular atrophy (SMA): State of art and new challenges. 21st July 2023, Rome, Italy 133
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 133
Timed Rise from Floor as a Predictor of Disease Progression in Duchenne Muscular Dystrophy: An Observational Study 133
Myostatin Levels in SMA Following Disease-Modifying Treatments: A Multi-Center Study 132
Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen 131
The Spinal Muscular Atrophy Health Index: Italian validation of a disease-specific outcome measure 131
Early treatment of type II SMA slows rate of progression of scoliosis 130
Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy 130
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 129
Revised north star ambulatory assessment for young boys with Duchenne muscular dystrophy 129
Disease Trajectories in the Revised Hammersmith Scale in a Cohort of Untreated Patients with Spinal Muscular Atrophy types 2 and 3 128
Functional levels and MRI patterns of muscle involvement in upper limbs in Duchenne muscular dystrophy. 128
Prevalence of Duchenne muscular dystrophy in Italy: a nationwide survey 127
An observational study of functional abilities in infants, children, and adults with type 1 SMA. 126
Early Childhood Attention Battery: Italian adaptation and new expanded normative data. 126
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial 126
Longitudinal Analysis of PUL 2.0 Domains in Ambulant and Non-Ambulant Duchenne Muscular Dystrophy Patients: How do they Change in Relation to Functional Ability? 126
Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53 125
Respiratory Trajectories in Type 2 and 3 Spinal Muscular Atrophy in the iSMAC Cohort Study 125
2-Year Change in Revised Hammersmith Scale Scores in a Large Cohort of Untreated Paediatric Type 2 and 3 SMA Participants 124
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 124
Language Development in Preschool Duchenne Muscular Dystrophy Boys 124
A critical review of patient and parent caregiver oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in spinal muscular atrophy 124
Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy 123
High Expression of SMN circ4-2b-3 in SMA I Children Treated with Nusinersen is Associated with Improved Motor Outcomes 122
A Longitudinal Follow-Up Study of Intellectual Function in Duchenne Muscular Dystrophy over Age: Is It Really Stable? 122
Nusinersen in pediatric and adult patients with type III spinal muscular atrophy 122
Language Development in Preschool Duchenne Muscular Dystrophy Boys 121
Assessment of early attention in an Italian cohort of preschooler preterm children using the Early Childhood Attention Battery 121
Does albuterol have an effect on neuromuscular junction dysfunction in spinal muscular atrophy? 121
Body mass index in type 2 spinal muscular atrophy: a longitudinal study 120
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 119
Ambulatory function in spinal muscular atrophy: Age-related patterns of progression. 118
Developmental milestones in type I spinal muscular atrophy 114
Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial 113
Clinical Variability in Spinal Muscular Atrophy Type III. 113
Sleep disorders in spinal muscular atrophy 111
Development of an International SMA Bulbar Assessment for Inter-professional Administration 111
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 111
Longitudinal Motor Functional Outcomes and Magnetic Resonance Imaging Patterns of Muscle Involvement in Upper Limbs in Duchenne Muscular Dystrophy. 111
Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis 111
Revised upper limb module for spinal muscular atrophy: Development of a new module 109
Longitudinal natural history in young boys with Duchenne muscular dystrophy 109
Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis 107
An observational study of functional abilities in infants, children, and adults with type 1 SMA 106
Longitudinal Analysis of PUL 2.0 Domains in Ambulant and Non-Ambulant Duchenne Muscular Dystrophy Patients: How do they Change in Relation to Functional Ability? 106
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 105
Communicative development inventory in type 1 and presymptomatic infants with spinal muscular atrophy: a cohort study 103
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 102
Development of an academic disease registry for spinal muscular atrophy 102
Risdiplam in Type 1 Spinal Muscular Atrophy 101
P.222Long term progression in type II spinal muscular atrophy: a retrospective observational study 101
Italian survey on evolving SMA care with disease-modifying therapies: a consensus workshop on nutrition, swallowing, respiratory and rehabilitation care 101
Patient reported outcome measure for upper limb in Duchenne muscular dystrophy: correlation with PUL2.0 98
Determining minimal clinically important differences in the Hammersmith Functional Motor Scale Expanded for untreated spinal muscular atrophy patients: An international study 98
North Star Ambulatory Assessment changes in ambulant Duchenne boys amenable to skip exons 44, 45, 51, and 53: A 3 year follow up 97
Changes in abilities over the initial 12 months of nusinersen treatment for type II SMA 96
Clinical Phenotype of Pediatric and Adult Patients With Spinal Muscular Atrophy With Four SMN2 Copies: Are They Really All Stable? 94
An observational study of functional abilities in infants, children, and adults with type 1 SMA 93
Gain and loss of abilities in type II SMA: A 12-month natural history study 93
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 92
Totale 14.985
Salva come PNG Salva come JPEG
Categoria #
all - tutte 69.561
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 69.561
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202116 0 0 0 0 0 0 0 0 0 0 15 1
2021/2022693 45 7 15 92 52 27 17 95 50 41 122 130
2022/20232.030 179 245 123 273 135 262 143 182 277 37 102 72
2023/20241.666 60 299 70 140 76 297 196 83 42 86 130 187
2024/20253.182 64 53 217 197 247 170 166 135 425 251 668 589
2025/20269.829 954 294 588 1.277 1.793 1.997 1.453 427 468 508 70 0
Totale 17.738